Skip to main content
. Author manuscript; available in PMC: 2014 Oct 3.
Published in final edited form as: Semin Arthritis Rheum. 2013 Jun 3;43(2):137–143. doi: 10.1016/j.semarthrit.2013.02.002

Table 2.

Point prevalence of RA patients in Remission according to Subgroups Defined by RA Treatments and Various Comorbidities

Total, n Prevalence of Remission, % p-value*
DMARD/Biologic treatment <0.001
 MTX 7301 9
 MTX + HCQ 1,435 11
 MTX + HCQ + SSA ± Lef 174 5
 MTX + SSA 239 7
 Lef ± (HCQ + SSA) 777 6
 Non-TNF Biologic 732 4
 Non-TNF Biologic + Lef ± (HCQ + SSA) 206 3
 Non-TNF Biologic + MTX 974 6
 Non-TNF Biologic + MTX + HCQ ± SSA 124 2
 Anti-TNF monotherapy 2,889 10
 Anti-TNF + Lef ± (HCQ + SSA) 559 8
 Anti-TNF + MTX 5,469 11
 Anti-TNF + MTX + HCQ ± (SSA + Lef) 586 6
Prednisone (mg/day) <0.001
 None 22,285 10
 < 5 1,777 6
 5–9 2,803 4
 ≥ 10 1,365 1
COPD <0.001
 Yes 432 3
 No 20,576 10
Diabetes <0.001
 Yes 2,357 5
 No 25,696 9
Heart Failure <0.001
 Yes 407 2
 No 27,646 8
Smoking, <0.001
 Current 4,294 5
 Not current 15,388 8

MTX = methotrexate; HCQ = hydroxychloroquine; SSA = sulfasalazine; Lef = leflunomide; anti-TNF = anti-tumor necrosis alpha; non-anti-TNF biologic = abatacept, rituximab and tocilizumab combined COPD = Chronic Obstructive Pulmonary Disease

*

p-value calculated using Chi-squared